130 related articles for article (PubMed ID: 20072938)
1. Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer.
Chua W; Moore MM; Charles KA; Clarke SJ
Curr Opin Mol Ther; 2009 Dec; 11(6):611-22. PubMed ID: 20072938
[TBL] [Abstract][Full Text] [Related]
2. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
[TBL] [Abstract][Full Text] [Related]
4. Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies.
Hawkes E; Cunningham D
J Clin Oncol; 2010 Oct; 28(28):e529-31; author reply e532-e533. PubMed ID: 20679615
[No Abstract] [Full Text] [Related]
5. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
Bardelli A; Siena S
J Clin Oncol; 2010 Mar; 28(7):1254-61. PubMed ID: 20100961
[TBL] [Abstract][Full Text] [Related]
6. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
[TBL] [Abstract][Full Text] [Related]
7. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
De Roock W; De Vriendt V; Normanno N; Ciardiello F; Tejpar S
Lancet Oncol; 2011 Jun; 12(6):594-603. PubMed ID: 21163703
[TBL] [Abstract][Full Text] [Related]
8. Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer.
Perkins G; Pilati C; Blons H; Laurent-Puig P
Pharmacogenomics; 2014 May; 15(7):1043-52. PubMed ID: 24956256
[TBL] [Abstract][Full Text] [Related]
9. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
[TBL] [Abstract][Full Text] [Related]
10. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
Ince WL; Jubb AM; Holden SN; Holmgren EB; Tobin P; Sridhar M; Hurwitz HI; Kabbinavar F; Novotny WF; Hillan KJ; Koeppen H
J Natl Cancer Inst; 2005 Jul; 97(13):981-9. PubMed ID: 15998951
[TBL] [Abstract][Full Text] [Related]
11. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
[TBL] [Abstract][Full Text] [Related]
12. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway.
Russo A; Rizzo S; Bronte G; Silvestris N; Colucci G; Gebbia N; Bazan V; Fulfaro F
Oncology; 2009; 77 Suppl 1():57-68. PubMed ID: 20130433
[TBL] [Abstract][Full Text] [Related]
13. The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma.
Silvestris N; Tommasi S; Petriella D; Santini D; Fistola E; Russo A; Numico G; Tonini G; Maiello E; Colucci G
Oncology; 2009; 77 Suppl 1():69-74. PubMed ID: 20130434
[TBL] [Abstract][Full Text] [Related]
14. Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?
Hawkes E; Cunningham D
Lancet Oncol; 2010 Nov; 11(11):1020-1. PubMed ID: 21051017
[No Abstract] [Full Text] [Related]
15. Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patients.
Er TK; Chen CC; Bujanda L; Herreros-Villanueva M
Biomed Res Int; 2014; 2014():591867. PubMed ID: 25032217
[TBL] [Abstract][Full Text] [Related]
16. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
Pander J; Gelderblom H; Antonini NF; Tol J; van Krieken JH; van der Straaten T; Punt CJ; Guchelaar HJ
Eur J Cancer; 2010 Jul; 46(10):1829-34. PubMed ID: 20418097
[TBL] [Abstract][Full Text] [Related]
17. Molecular markers predictive of chemotherapy response in colorectal cancer.
Shiovitz S; Grady WM
Curr Gastroenterol Rep; 2015 Feb; 17(2):431. PubMed ID: 25663616
[TBL] [Abstract][Full Text] [Related]
18. Beyond the KRAS test.
Laurent-Puig P; Lièvre A; Blons H
Eur J Cancer; 2009 Sep; 45 Suppl 1():398-9. PubMed ID: 19775645
[No Abstract] [Full Text] [Related]
19. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
20. Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment.
Dienstmann R; Tabernero J
Cancer J; 2016; 22(3):149-55. PubMed ID: 27341591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]